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CONGRESS HIGHLIGHTS
EPIDEMIOLOGY AND ENVIRONMENT
Multiomic studies in epidemiology: what can they tell us?
The increasing use of multiomics in the field of the molecular epidemiology of lung health was nicely
illustrated during this session. Covering both asthma and chronic obstructive pulmonary disease (COPD),
the studies presented during this session showed novel findings on the genetics of these diseases using
innovative genomic approaches including genetic risk scores (GRS), genome-wide interaction (GWI)
studies and identification of rare genetic variants.
The usefulness of a GRS for COPD recently reported by WAIN et al. [1] was demonstrated by two
speakers. WAIN [2] presented an extended version of her COPD GRS with 139 novel signals and a
weighted risk score based on 279 variants. The weighted risk score was significantly associated with risk of
COPD, with an odds ratio of 1.55 (95% CI 1.47–1.63) for each standard deviation of the risk score. Using
data from the SPIROMICS study, Elizabeth Oelsner reported that the GRS from WAIN et al. [1] was not
only associated with lung function, but also with computed tomography (CT) scan measures such as lung
density, spatially matched airway dimensions and small airway counts [3]. In addition, she suggested that
variation in lung structure could be an important mediator of genetic risk factors underlying COPD.
Interestingly, Natalie Terzikhan showed that the diffusing capacity of the lung for carbon monoxide
(DLCO) may also be heritable and is significantly associated with a genetic variant in GPR126 [4].
Terzikhan reported that the expression of this gene was decreased in lung tissue of patients with COPD,
but whether GPR126 has a functional role in COPD is unclear.
Three studies focused on the aetiology of asthma but used different approaches to improve our
understanding of the development of this disease. Emmanuelle Bouzigon reported on the findings of a
meta-analysis of five GWI studies combined with survival analysis carried out to identify genetic variants
that interact with sex and associate with time to asthma onset. One female-specific and two male-specific
variants were identified, all involved in inflammatory processes and immune cell regulation [5]. Cosetta
Minelli showed results from a Mendelian randomisation study using UK Biobank data and provided
evidence that early puberty has detrimental effects on asthma [6]. As these effects were observed in both
sexes, it is unlikely that female sex hormones act as mediators of this causal association. Using data from
the Avon Longitudinal Study of Parents and Children cohort, and after assessing the association between
maternal dietary antioxidant intake during pregnancy and childhood asthma [7], Annabelle Bédard
reported that maternal intake of zinc might be associated with better lung function of the offspring.
The last two speakers of this session presented results from studies that aimed to identify rare genetic
variants associated with COPD and asthma. Maaike de Vries selected rare genetic variants that were
predicted to be pathogenic and present in at least three individuals within a small homologous population
of 36 never-smokers with COPD. Two of these rare genetic variants in the genes ARAP3 and KIF27 were
associated with COPD in two general population-based cohorts (LifeLines and the Rotterdam Study) [8].
Finally, Diana Chang, who looked at common and rare variant burden GWAS in a large group of people
of European ancestry living with asthma, reported a novel variant in THSD4 associated with asthma risk.
In addition, she showed a significant enrichment of genes implicated in primary ciliary dyskinesia with
asthma risk among patients with low eosinophil counts [9].
What is the clinical relevance of these findings? What do they tell us about the underlying mechanisms of
COPD and asthma? For now, these questions remain unanswered but they do give clues and generate
hypotheses for further testing, eventually in epidemiological studies combining genetics with epigenetics,
transcriptomics and other ’omics of respiratory disease.
COPD and chronic respiratory disease: from misclassification to radiological
findings
The research presented in this session highlighted great advances in the understanding of chronic
respiratory diseases, and the growing complexity and systemically entangled nature of their prevention,
morbidity and management.
BACKMAN et al. [10] investigated the prevalence of COPD in Sweden following decades of smoking decline
using data from the West Sweden Asthma Study and the Obstructive Lung Disease in Northern Sweden
study. Backman reported a decrease in the prevalence of COPD from 11–17% to 5.6–8.4%, a noticeable
change since the turn of the millennium. As cigarette smoking is the main risk factor for COPD [11], she
suggested that smoking decline in Sweden over the last decades is the main driving force behind this
decline in the prevalence of COPD.
Several polymorphisms of the FAM13A gene have previously been associated with increased lung function
decline in smokers [12]. Using data from the Korean Genome Epidemiology Study, KIM et al. [13] tracked
lung function decline in ∼2900 male current and former smokers over 16 years. In this study, participants
had been genotyped for the single-nucleotide polymorphism rs3756050 of FAM13A. Kim reported that
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while all former smokers benefited from reduced lung function decline, former smokers homozygous for
the nonrisk allele experienced significantly less lung function decline compared to those with at least one
risk allele.
Not smoking is perhaps the most effective means of COPD prevention but other lifestyle factors may also
influence risk. Recent research has suggested that increased fruit and vegetable intake is associated with
decreased risk of COPD in current and former smokers [14]. METERAN et al. [15] used data on 11458
adults from the Danish Twin Registry to investigate whether this association was due to underlying genetic
factors. Meteran showed that increasing self-reported intake of fruit and raw vegetables was significantly
associated with decreased risk of COPD. Whether this association is explained by genetic factors is
difficult to say since results from the cotwin analysis, designed to determine the influence of genetics, were
inconclusive.
The relationship between chronic respiratory diseases and cardiovascular diseases may be mediated by
inflammation [16], which may activate coagulation. Yet, little is known about the role of coagulants in
chronic respiratory diseases such as COPD. Gunnar Husebø presented findings from work he and his
colleagues carried out using data from the Bergen COPD Cohort Study. The aim was to investigate
coagulation markers as potential biomarkers for acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) [17]. They found that thrombin–antithrombin (TAT) complex, activated protein
C–protein C inhibitor and D-dimer were all at significantly higher concentrations during AECOPD than
in the stable state. Additionally, higher TAT in stable state was associated with an increased AECOPD
frequency, while higher D-dimer was associated with increased mortality.
Logical fallacies resultant from a lack of research are easily made when attempting to manage patients with
multimorbidity due to shear complexity and the desire to do no harm. Fears that β-blockers would
increase bronchoconstriction led to their underuse in COPD patients; however, numerous studies have
now shown that β-blockers are safe [16]. RASMUSSEN et al. [18] examined nationwide β-blocker prescribing
practices post-myocardial infarction in Denmark from 1995–2015. They found that β-blockers are still
systematically underused in COPD patients but that their utilisation has increased over time.
Morbidity and mortality due to chronic respiratory diseases is a significant public health burden [19, 20].
Nils Hoyer presented findings from a study where, using data from the Danish Lung Cancer Screening
Trial, he and colleagues investigated the most likely causes of hospital admission in smokers with
interstitial lung abnormalities (ILAs) [21]. Hoyer reported that those with ILA were more likely to be
admitted to hospital than those without ILA, and that the most common diagnoses resulting from these
admissions were respiratory (COPD, pneumonia, lung abscess and interstitial lung disease), cardiovascular
(heart failure, pulmonary embolism and peripheral vascular disease) and malignant (lung cancer) disease.
GAYLE et al. [22] examined causes of death in chronic respiratory disease patients from the Clinical
Practice Research Datalink in the UK. Gayle reported that from 2005 to 2014, while deaths due to
circulatory diseases decreased, deaths due to respiratory diseases remained constant. These trends may
reflect how, unlike circulatory diseases, respiratory medicine has not benefited from the development of
disease-modifying interventions.
Occupational and environmental lung diseases: from early influences and novel
exposures to preventive approaches
This session brought together speakers from Europe, North America and Africa to talk about respiratory
diseases and their links mainly to occupational exposures. It covered studies of several diseases on several
continents, the use of media to increase awareness of occupational disease and guidelines on how to deal
with occupational asthma.
Sara de Matteis presented the results of an update of the British Occupational Health Research Foundation
guidelines on occupational asthma [23]. De Matteis performed a systematic review, qualitatively appraised
using the Grading of Recommendations, Assessment, Development and Evaluations scoring system, and
produced evidence-based statements and recommendations for all stakeholders. She reported that the
occupational asthma incidence (1.6–300 cases per million workers) has remained stable over time and that
the best occupational asthma prevention intervention is to control exposure to potential asthmagens in the
workplace. Serial peak expiratory flow measurements remain the recommended approach for occupational
asthma diagnosis, and early identification of cases via health surveillance and exposure avoidance to the
causal agents remain pivotal to cure or at least improve occupational asthma prognosis. De Matteis also
reported that, based on the systematic review, being a cleaner increases the risk of occupational asthma [23].
A relatively large and recent study of 2030 US healthcare workers supports this finding [24]. Paul
Henneberger reported that workers who were in charge of cleaning fixed surfaces were almost twice as
likely to have current asthma as those who do not carry out cleaning tasks. Administration of aerosolised
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medications was also associated with current asthma and asthma exacerbations. Individuals with allergic
diseases in childhood may have increased risk of work-related asthma in adulthood and would constitute a
relevant target group for specific interventions, including career advice.
The influence of asthma and allergies in childhood in avoiding occupational exposure in early adulthood
was examined in the prospective Melbourne Atopic Cohort Study, which included 363 participants with
high risk of asthma and allergies [25]. Orianne Dumas reported that there was no evidence of avoidance of
potentially hazardous exposures in young adults with a history of asthma or allergies, supporting the need
for improved counselling regarding career choices.
Using data from a small study of 68 former welding, plumbing and heating apprentices in Quebec,
Canada, Eva Suarthana examined the association between exposure to welding fumes and occupational
rhinitis 7–17 years post-apprenticeship [26]. Several methods were used to evaluate both exposure
(self-report, expert assessment and job–exposure matrix) and rhinitis (self-reported symptoms and peak
nasal inspiratory flow). Suarthana reported that although workers exposed to welding fumes seemed to be
at higher risk of rhinitis, the size of the study sample and the lack of statistical significance precluded any
firm conclusions.
People who work fitting insulation in buildings are a population at risk of both respiratory and
cardiovascular diseases, with asbestos as the most common occupational cause of morbidity and mortality
among this population. A longitudinal study of 301 never-smoking unionised insulators in Alberta,
Canada, showed that 54% of the insulators are exposed to asbestos. Samineh Kamravaei reported that
insulators showed a lower COPD Assessment Test score (mean 4±4 versus 6±5, p<0.001) and more lung
abnormalities on chest radiography (10% versus 3%, p<0.01) than controls (police officers). In addition,
the Framingham risk score (cardiovascular risk) in insulators older than 50 years was worse than that of
same-age controls [27].
Dust from artificial stone, which is widely used worldwide, especially in kitchen work surfaces, has been a
concern due to its ultrafine particles penetrating deeply in lungs. Noa Ophir presented the findings of a
study in 100 Israeli workers exposed to artificial stone dust for up to 20 years. He reported that a decline
in lung function values (total lung capacity, forced expiratory volume in 1 s (FEV1) and single-breath
DLCO), a worsening CT score [28], and elevated levels of inflammatory cytokines (interleukin-6,
interleukin-8 and tumour necrosis factor-α) [29] were associated with a greater number of nano-range
particles in induced sputum.
National administrative data can be useful in occupational lung disease epidemiology and intervention
planning. Jill Murray reviewed the Pathology Automation computerised database recording South Africa
miners’ pathological findings from autopsy since 1975 [30], combined with demographic and clinical data.
Murray reported that amongst 11901 records, 72% worked in gold mining. Amongst black miners,
silicosis and pulmonary tuberculosis (TB) prevalence increased over the period from 1975 to 2016.
Employment duration, increasing age and autopsy year related to silicosis trends, whilst pulmonary TB
was mainly affected by silicosis and HIV infection [31].
The European Lung Foundation, in collaboration with the European Respiratory Society (ERS), has
developed an online tool that may help in improving awareness of occupational respiratory diseases in
at-risk populations [32]. This tool was designed for members of the public to assess whether their
occupation may pose a risk to their lung health (http://yourlungsatwork.europeanlung.org/en/). According
to Emma Thompson, users invited through a social media advertising campaign targeting at-risk workers
were asked to answer a quiz online, including six questions on respiratory symptoms and their link with
work. Among >8000 participants, 89% were advised to talk to a healthcare professional after taking the
quiz and 10% reported that they had to leave or change their job in the past because of their breathing.
Effect of environmental exposure on lung function outcomes
In this session, results from several high-quality cohort studies examining the effects of tobacco smoke and
air pollution exposures on lung function were presented.
Elizabeth Oelsner [33] studied the effect of former and light smoking on lung function changes over time
in US population-based cohorts. Oelsner reported that lung function decline was faster among former and
light smokers compared to never-smokers, the effect being greater among the current light smokers.
Three longitudinal studies conducted in northern European countries, where pollutant concentrations are
relatively low (i.e. average below European Union recommendations), were presented and all suggested
adverse long-term effects of air pollution exposure on respiratory health [2–4]. Ane Johannessen presented
findings from the Respiratory Health in Northern Europe study [34], where she and her colleagues
investigated the effects of annual average concentrations of particulate matter (PM2.5 and PM10) and
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nitrogen dioxide on all-cause/respiratory sick leave 10 and 20 years later. PM2.5 and PM10 were found to
be associated with all-cause sick leave and respiratory-sick leave 20 years later, but not 10 years later. In an
urban Swedish population, Hanne Carlsen investigated the chronic effect of black carbon, PM2.5 and PM10
from different sources and found that traffic-related air pollution, particularly exposure to black carbon,
was associated with low forced vital capacity (FVC) and FEV1 [35]. Childhood as a critical window of
exposure was considered by Ingrid Kuiper. She and her co-workers investigated long-term effects of
exposure to PM2.5, PM10, NO2 and greenness in childhood on respiratory health in adulthood in the
RHINESSA cohort (Respiratory Health in Northern Europe, Spain and Australia) and showed that
early-life exposure to outdoor air pollution was associated with respiratory symptoms and late-onset
asthma in adulthood while those who resided closely to a greenspace during childhood had fewer
symptoms in adulthood [36].
Body composition is known to be associated with lung function decline [37–39]. However, whether
distinct body mass index (BMI) trajectories over time affect lung function decline is still unknown.
Gabriela Peralta identified different BMI trajectories during adulthood and examined their associations
with lung function decline in the European Community Respiratory Health Survey cohort [40]. Adults
who remained overweight or obese throughout the study and those who became overweight were found to
have greater lung function decline than those with a “normal” BMI throughout.
Most epidemiological studies have focused on single exposure–health effect relationships but the
“exposome” approach has attracted growing interest and has been leading to new ways of analysing
multiple exposures [41]. In the large European Human Early-Life Exposome cohort study, Valerie Siroux
and colleagues conducted the first exposome study on lung function in children [42]. Using data from
1200 mother–child pairs, they assessed 85 prenatal and 125 postnatal exposures (biomonitoring data,
geospatial data, sensor data, child health outcomes and ’omics signatures) and examined their effects on
FEV1. Siroux reported that some previously known associations, such as those between exposure to
phthalates and perfluoroalkoxyalkanes and FEV1 decline, were observed [42].
There is some evidence that the oral microbiota may influence respiratory health, especially in oral and
dental conditions such as periodontal disease [43–45]. In adults from the RHINESSA study, Oistein
Svanes identified 147 bacteria genera in the gingival fluid, and found associations between known oral and
lung pathogens and lower lung function [46], supporting the hypothesis that oral bacteria may perturb
pulmonary health either by entering the lungs through microaspiration or by infusing inflammatory
mediators from inflamed gingival epithelium to the lungs.
The use of a fixed cut-off for the FEV1/FVC ratio to define airflow limitation rather than the lower limit
of normal (LLN) may cause underdiagnosis among younger individuals [47], an issue that has been poorly
studied. Yunus Çolak investigated whether underdiagnosed airflow limitation in young and middle-aged
adults from the Copenhagen General Population Study was associated with a poorer prognosis [48], and
found that individuals diagnosed with airflow limitation based on the LLN but not the fixed ratio at
baseline had an increased risk of respiratory and cardiovascular morbidity and early death during
follow-up.
The findings presented in this session highlight the importance of using a long-term approach when
investigating the role of environmental or lifestyle factors, as well as the importance of using appropriate
clinical parameters to diagnose airflow limitation.
Innovative tobacco cessation approaches and trends in tobacco and e-cigarette use
Stopping smoking is challenging. However, evidence-based treatment delivered by trained healthcare
providers (HCPs), combining both behavioural counselling and pharmacotherapy, is effective in helping
smokers to achieve sustained abstinence [49]. Nevertheless, recent population-based surveys among
European countries reveal a decreasing trend of assisted quitting with the support of HCPs towards
unassisted quitting or the use of e-cigarettes [50]. In this session, three studies applying distinct
approaches to this topic were presented. Paraskevi Katsaounou reported on the results of a World Health
Organization (WHO)–ERS project on smoking cessation in primary care, which targeted three countries
with a high prevalence of tobacco use and low availability of cessation services (i.e. Bangladesh, Greece
and Moldova) [51]. The aim was to strengthen national health systems for treating tobacco dependence,
especially in primary care, by establishing a national network of HCPs adequately trained in smoking
cessation advice. This was achieved by engaging local government and health authorities, with the support
of ERS and WHO experts, to deliver “train the trainers” workshops in cessation brief advice. The
preliminary results of the first year show both wide reach and effectiveness, enrolling >10000 smokers in
the three countries, and achieving successful high abstinence rates at 1 month (31.7% to 48.4%) [51, 52].
This project also highlights the win–win opportunity for partnerships in tobacco control, maximising
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resources and expertise, implementing the broad reach and most cost-effective clinical interventions, and
supporting those countries with the most need. VAN SCHAYCK et al. [53] used a cluster randomised trial to
investigate the impact of financial incentives offered through a workplace-based smoking cessation
programme implemented in 61 companies in the Netherlands (640 smokers). The smokers in the
intervention arm attended seven 90-min cessation counselling sessions and received three €50 incentives:
immediately after completing the programme, and 3 and 6 months later. Those in the control arm were
provided with the counselling sessions but not the financial incentives. Van Schayck reported that the
proportion of quitters was higher in the intervention arm, especially in the long term. This is a successful
example of both health-promoting working places and real-world smoking cessation programmes, using
the strategies of the Ottawa Charter [54], i.e. strengthening community actions and creating supportive
environments. Finally, a randomised clinical trial carried out in Ireland assessed the effectiveness of the
empirical, widely used and nonvalidated Allen Carr’s Easyway to Stop Smoking method [55], which does
not include pharmacotherapy [56]. The main aim of the study (300 smokers) was to assess whether this
method, delivered in a group setting, would achieve higher abstinence rates than the Irish online Quit
programme developed by the Irish National Health Services (www.quit.ie). Sheila Keogan reported that the
Allen Carr method achieved significantly higher quit rates, both in the short and long terms. Further
research on this method in other populations is recommended.
In this session, trends in tobacco and e-cigarette use from population-based surveys in Sweden, France and
Russia were also presented. Emma Goksor reported that while in 2008, a postal questionnaire-based survey
observed an alarming increase in young female smoking rates, in 2016, a repeat survey shows a decreasing
trend in the same age group (16–25 years) from 20.5% to 15.2% [57]. Additionally, the sex gap in smoking
prevalence has narrowed over time. However, the study observed that current smokers, in comparison to
those interviewed in 2008, and females, in comparison to males, reported respiratory symptoms more
often [57]. This trend is in line with recent research and points out that women may be more vulnerable
than men to tobacco health hazards, and that cigarettes became more toxic over time [58]. Linnea
Hedman presented findings from a study on use of e-cigarettes by schoolchildren carried out in Northern
Sweden [59]. She reported that the prevalence of current smoking among boys and girls was ∼10%.
Current e-cigarette use was more common in boys, ever-smokers and snus users, and less common among
those with a healthy diet. Although use of e-cigarettes was more common among ever-users of any
tobacco product, 39% of current e-cigarette users at age 19 years were nonsmokers, which suggests that
e-cigarettes are substituting traditional cigarettes among youth. Emeline Lequy presented findings from the
Constances study, in which LEQUY et al. [60] investigated the determinants of e-cigarette use, particularly
exploring associations with health conditions. Among 18300 participants, who were either ever-users of
tobacco or current users of e-cigarettes, ∼17% of current smokers and ∼4% of former smokers used
e-cigarettes. The major predictors of e-cigarette use were age, with young adults reporting the highest
prevalence, increasing cumulative tobacco consumption and suffering from respiratory conditions. Finally,
Marine Gambaryan presented the findings of the Russian Tobacco Control Law Evaluation Survey on the
use of e-cigarettes. Among 11699 participants, ∼12% had ever used e-cigarettes and almost 26% of those
were regular users [61]. Among cigarette smokers, ∼44% had tried to quit using e-cigarettes but more than
two-thirds failed to reduce cigarette consumption. Finally, the study shows that while most participants
were against vaping in indoor public and private places, a significant proportion witness vaping in public
places and the majority had been exposed to vaping aerosols in public places where smoking is legally
banned [61].
Emergent tobacco products and harm reduction: a tobacco solution to a
tobacco problem?
In this Hot Topic session, the focus was on heated tobacco products (HTPs), and the pros and cons of using
them. The first speaker, Dimos Fotopoulos, talked about the main role of nicotine addiction in maintaining
tobacco consumption, as well as harm reduction principles and its public health applications [62].
Addiction is a chronic phenomenon of brain reward, motivation, memory and related circuitry [63]. Most
tobacco products, including HTPs and e-cigarettes, are devices of inhaled nicotine, which is highly
addictive and poses challenges to treatment interventions [64]. Some approaches to quitting smoking
promote minimisation of risks and harms of tobacco use but without motivation and promotion of a
healthy lifestyle, satisfactory health outcomes are difficult to achieve. According to Dimos Fotopoulos,
emergent tobacco and nicotine delivery devices with allegedly harm reduction potential are examples of
inadequate harm reduction approaches as they do not encourage nicotine cessation and rather stimulate
the continuation of nicotine use.
The second speaker, Linnea Hedman, discussed causality in public health science and reviewed the
evidence on the potential human health effects of HTPs [65]. Public health advocates have stressed that
the short- and long-term health effects resulting from continued consumption of addictive products such
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as HTPs remain unclear. Moreover, given the tobacco industry’s long history of deceit about tobacco
health hazards [66], there is an urgent need for independent research and robust scientific evidence on
these products. To date, few independent studies have explored the components or the emissions of HTPs
or studied the health effects of these products in animal models. However, Hedman suggested that
scientific uncertainty should not be used as a reason to postpone preventive measures and that the
precautionary principle should be applied to stop HTPs from being used.
Elif Dagli talked about industry tactics focusing on harm reduction and the development of novel HTPs [67].
In 2015, the profits of six major tobacco companies reached USD 62 billion. In the same year, 6.4 million
people died due to tobacco-related diseases [68]. In an attempt to improve its image, the industry is trying
to eliminate cigarettes, replacing them with smoke-free e-cigarettes, and to reduce tobacco-related
mortality. They have been funding research, scientific meetings and publications. For example, Philip
Morris has committed USD 80 million from 2018 to 2029 to the Foundation for a Smoke-Free World,
whose goal is to eliminate smoking worldwide, and advance smoking cessation and harm-reduction
science and technology [68–70]. A survey of tobacco industry documents by Stanton Glantz and
colleagues showed that the tobacco industry’s early HTP pursuits were primarily driven by non-health
related reasons, in particular to evade smoke-free regulations and to complement, rather than compete
with, conventional cigarettes [71]. Other research of tobacco industry documents by Anna Gilmore and
colleagues revealed that tobacco industry’s use of harm reduction was aimed to gain access to scientists,
the public health community and policy makers, and rebuild its reputation [72]. According to Dagli, HTPs
are not risk free, their use could renormalise tobacco use and there is no evidence to suggest they will
reduce the use of cigarettes. She concluded that tobacco industry tactics have not changed.
Isabel Saraiva gave a patient’s perspective on emerging tobacco and nicotine products [73]. She stressed
that smokers suffering from a lung condition need help and support from HCPs to quit. Isabel presented
herself as “an ex-heavy smoker” suffering from COPD and stated that when she decided to quit, neither
e-cigarettes nor HTPs were on the market. She also said: “I managed to quit for life. I doubt that I would
have stopped inhaling nicotine if these products were available. There are neither harmless tobacco nor
safe nicotine inhaled products”.
The last speaker in this session was Charlotta Pisinger, who presented the WHO and the Tobacco Control
Committee (TCC) position on HTPs [74]. The WHO and the WHO Framework Convention on Tobacco
Control (FCTC) Secretariat have clearly warned that HTPs are addictive, have been marketed “in pursuit
of profit rather than public health”, and should be subjected to the same policy and regulatory measures
applied to tobacco products, in line with the FCTC [75]. As the leading respiratory medical organisation,
ERS works strategically in tobacco control and promotes tobacco cessation, both from a policy and clinical
approach [52]. Charlotta Pisinger presented the TCC statement on HTPs and announced that they are
preparing another on harm reduction to be submitted for approval by the ERS leadership.
Concluding remarks
Asthma and COPD are still the two most heavily studied diseases in the field of respiratory epidemiology.
Recent findings on the genetics of both diseases have provided us with more questions than answers and
have shown that to understand the molecular mechanisms of these diseases, new studies should bring
together genetics, epigenetics, transcriptomics, other ’omics and epidemiological methods. Novel areas of
research, such as the exposome or the microbiome, could help to further understand the interplay of
respiratory disease and lung function with various environmental and lifestyle risk factors. Research on
shared genetic and environmental risk factors for the co-occurrence of chronic respiratory disease with
other diseases is limited and should be promoted. In addition, findings from studies on new nicotine
products and innovative ways to quit smoking emphasise that all tobacco and e-cigarette products are
additive and harmful. We hope that this summary of the remarkable amount of research in the field of
respiratory disease epidemiology and tobacco control presented through the Epidemiology and
Environment Assembly of the ERS creates curiosity to follow up on topics of interest to each reader.
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